Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TLR2 | O60603 | 4/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.41 |
| ▸ | GLP1R | P43220 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14086291 | 0.94 | KMT2A (0.56) | KMT2ATLR2SIRT2GLP1R | |
| SCHEMBL14073977 | 0.94 | KMT2A (0.55) | KMT2ATLR2SIRT2PTGER4CAPN1 | |
| SCHEMBL14073973 | 0.93 | KMT2A (0.55) | KMT2ATLR2SIRT2 | |
| SCHEMBL14073978 | 0.92 | KMT2A (0.54) | KMT2ATLR2SIRT2GLP1R | |
| SCHEMBL14073979 | 0.87 | KMT2A (0.49) | KMT2ATLR2SIRT2CAPN1CAPN2 | |
| SCHEMBL19662717 | 0.86 | KMT2A (0.57) | KMT2ATLR2 | |
| SCHEMBL14073721 | 0.84 | KMT2A (0.54) | KMT2ATLR2SIRT2 | |
| SCHEMBL24235593 | 0.84 | KMT2A (0.62) | KMT2ATLR2PTGER4 | |
| SCHEMBL14086305 | 0.83 | KMT2A (0.54) | KMT2ATLR2SIRT2 | |
| SCHEMBL30020899 | 0.82 | KMT2A (0.53) | KMT2ATLR2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234464-A1 | Compound Having Amino Acid Residue or Peptide Residue and Process for Producing the Same | CREDIA JAPAN CO., LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234464-A1 | Compound Having Amino Acid Residue or Peptide Residue and Process for Producing the Same | NGLY1, ELOVL6, ELOVL1 | KMT2A 1414/4885TLR2 1099/4885SIRT2 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.